肿瘤药学2024，Vol.14Issue(6)：695-701,7.DOI:10.3969/j.issn.2095-1264.2024.06.07
ⅠA期肺腺癌临床高危因素及术后辅助治疗研究进展
A review on clinical high-risk factors and postoperative adjuvant therapy in stage ⅠA lung adenocarcinoma
陈火育 1程磊 1彭东阁 2孙伟2
作者信息
- 1. 海南医科大学,海南 海口,570216
- 2. 海南医科大学第二附属医院 胸外科,海南 海口,570216
- 折叠
摘要
Abstract
The existing guidelines do not recommend postoperative adjuvant therapy for patients with stage ⅠA lung ade-nocarcinoma.However,patients with stage ⅠA lung adenocarcinoma containing clinical high-risk factors have a higher risk of recurrence and metastasis,and surgery alone may not be sufficient to ensure long-term efficacy.How and when to carry out postoperative adjuvant therapy to improve the survival of stage ⅠA patients with high risk of recurrence become a problem that needs to be solved in the future.This article will discuss the research progress of the prognosis and postoperative adjuvant therapy of stage ⅠA lung adenocarcinoma patients with high-risk factors(T stage,consolidation tumor ratio,high-grade path-ological subtypes and percentage,spread through air space,lympho-vascular invasion,etc.).关键词
肺腺癌/高危因素/预后/辅助治疗Key words
Lung adenocarcinoma/Risk factor/Prognosis/Adjuvant therapy分类
医药卫生引用本文复制引用
陈火育,程磊,彭东阁,孙伟..ⅠA期肺腺癌临床高危因素及术后辅助治疗研究进展[J].肿瘤药学,2024,14(6):695-701,7.
